




# PHARMACEUTICAL 2021

Ovid Therapeutics Inc.  
Rank 296 of 402





# PHARMACEUTICAL 2021

Ovid Therapeutics Inc.  
Rank 296 of 402



The relative strengths and weaknesses of Ovid Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ovid Therapeutics Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Ovid Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is -11%, being 58% points below the market average of 47%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 74,843            |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 22,063            |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 947               |
| Other Compr. Net Income                     | -2.5              |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 10,231            |
| Other Net Income                            | 395               |
| Other Revenues                              | 12,617            |
| Property and Equipment                      | 136               |
| Research and Development                    | 63,417            |
| Selling, General and Administrative Expense | 30,631            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 75,926            |
| Liabilities              | 32,294            |
| Expenses                 | 94,048            |
| Revenues                 | 12,617            |
| Stockholders Equity      | 43,632            |
| Net Income               | -81,036           |
| Comprehensive Net Income | -81,037           |
| Economic Capital Ratio   | -11%              |